Skip to main content
TipRanks
Go Ultimate75% OFF

Amur Minerals (CRTX) AI Stock Analysis

12 Followers
GB:CRTX

Amur Minerals

(LSE:CRTX)

Select Model
Rating:49Neutral
Price Target:GBX 8.50▲(3.03% Upside)
Action:reiterated
Date:09/18/26

The low overall score is driven primarily by very weak financials, including persistent losses, heavy cash burn and a significantly weakened equity base, with an uncertain valuation due to negative earnings and no dividend support; technical indicators are only moderately negative and provide limited offset, resulting in a high-risk profile despite some stabilization in price dynamics.

Positive Factors
Debt-free balance sheetThe absence of financial debt reduces refinancing exposure and interest obligations, giving the company greater flexibility while it advances its mineral assets. This provides some protection against balance-sheet stress, although it does not eliminate the need for external funding.
Negative Factors
No recurring production revenueWithout an operating mine, the company lacks recurring metal-sale revenue to fund exploration and corporate costs. The 2025 revenue of zero highlights dependence on project advancement or transactions rather than an established operating business with predictable inflows.

Amur Minerals (CRTX) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-20%0%20%40%60%GB:CRTX-31.25%EWC+13.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 6.39M
Dividend Yield
―
Average Volume (3M)
96.04K
Price to Earnings (P/E)
-1.7
Beta (1Y)
0.71
Revenue Growth
―
EPS Growth
-6.87%
Country
UK
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Amur Minerals Business Overview & Revenue Model

Company Description

CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor o...

How the Company Makes Money

Amur Minerals’ business model is typical of an exploration-stage mining company: it seeks to create value by acquiring, exploring, delineating, and advancing mineral projects toward development or monetization. For much of its history, the company ha...

Amur Minerals Financial Statement Overview

Summary

Financial performance is very weak: the company is persistently loss-making with minimal revenue, deeply negative margins, ongoing cash burn and sharply eroded equity, partly offset by a debt-free balance sheet.

Income Statement

8Very Negative

Balance Sheet

30Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Jun 2023Jun 2022
Income Statement
Total Revenue0019.98K56.88K00
Gross Profit-13.46K-117.00K16.78K-3,79200
EBITDA-2.73M-2.09M-449.07K―-1.95M-1.75M
Net Income-2.39M-1.90M-485.05K-247.74K-2.45M-1.54M
Balance Sheet
Total Assets2.92M1.80M1.82M160.53K23.89M31.24M
Cash, Cash Equivalents and Short-Term Investments2.27M1.13M1.28M1,2642.90M4.93M
Total Debt000496.75K00
Total Liabilities343.00K381.00K341.00K920.19K765.65K1.13M
Stockholders Equity2.58M1.42M1.48M4.12M23.13M30.11M
Cash Flow
Free Cash Flow-2.58M-1.97M-961.00K-2.77M-2.99M-2.26M
Operating Cash Flow-2.58M-1.97M-933.00K-2.77M-3.35M-1.83M
Investing Cash Flow35.00K-31.00K2.33M34.93M-511.00K6.04M
Financing Cash Flow4.47M1.84M-67.00K-31.45M968.00K0

Amur Minerals Technical Analysis

Technical Analysis SentimentNegative
Last Price8.25

Price Trends

50DMA9.21Negative
100DMA9.77Negative
200DMA10.97Negative

Market Momentum

MACD-0.21Negative
RSI39.65Neutral
STOCH50.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRTX, the sentiment is Negative. The current price of 8.25 is below the 20-day moving average (MA) of 8.61, below the 50-day MA of 9.21, and below the 200-day MA of 10.97, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRTX.

Amur Minerals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:CRTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:CRTXGB:CRTX49NeutralGBP 6.57M-1.66-119.45%――-6.87%
GB:CIZGB:CIZ39UnderperformGBP 5.40M-7.03192.61%――42.86%
GB:NFXGB:NFX39UnderperformGBP 1.70M-1.38-83.53%――93.02%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:CRTXGB:NFXGB:CIZDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:CRTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:CRTXAmur Minerals8.25-3.75-31.25%
GB:NFXNuformix Plc0.07-0.24-79.03%
GB:CIZCizzle Biotechnology Holdings PLC1.13-0.52-31.82%

Amur Minerals Corporate Events

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

CRISM Therapeutics Issues New Equity Ahead of ChemoSeed Trial Progress

Positive
Oct 15, 2026

CRISM Therapeutics Corporation has agreed to issue 472,222 new ordinary shares at 9 pence per share to a consultant, expanding its equity base as it advances its clinical-stage oncology drug delivery platform. The new shares are expected to be admitt...

Business Operations and StrategyShareholder Meetings

CRISM Therapeutics Sets AGM Date as Phase 2 Glioblastoma Trial Recruitment Begins

Positive
Oct 2, 2026

CRISM Therapeutics Corporation has called its Annual General Meeting for 27 October 2026 in London, with the formal notice now posted to shareholders and available on the company’s website. The meeting underlines routine governance for the AIM-quoted...

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance

CRISM Therapeutics advances Phase 2 glioblastoma trial and strengthens funding for ChemoSeed platform

Positive
Sep 21, 2026

CRISM Therapeutics reported encouraging progress in the first half of 2026, highlighted by the opening of its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in resectable glioblastoma and the start of patient recruitment. The study...

Business Operations and StrategyExecutive/Board Changes

CRISM Therapeutics names seasoned healthcare dealmaker as chair amid Phase 2 trial push

Positive
Sep 17, 2026

CRISM Therapeutics has appointed experienced healthcare executive Dr Charles Spicer as Non-Executive Chair, effective 1 October 2026, with Interim Executive Chairman Andrew Webb returning to his role as chief executive. Spicer’s 25-year track record...

Business Operations and StrategyProduct-Related Announcements

CRISM Therapeutics Starts Phase II ChemoSeed Trial in Glioblastoma

Positive
Aug 20, 2026

CRISM Therapeutics has activated the first clinical site for its Phase II trial of irinotecan ChemoSeed in glioblastoma, marking a key step in moving its lead localised chemotherapy platform into active patient recruitment. The company’s immediate fo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 18, 2026